

Yusuke Kanemasa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7089577/publications.pdf>

Version: 2024-02-01

16
papers

244
citations

1040056

9
h-index

996975

15
g-index

18
all docs

18
docs citations

18
times ranked

480
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma. <i>Medicine (United States)</i> , 2022, 101, e29028.	1.0	1
2	Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 485-493.	2.2	32
3	Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma. <i>Medicine (United States)</i> , 2021, 100, e27733.	1.0	2
4	Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 309-317.	1.7	26
5	Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma. <i>Hematological Oncology</i> , 2019, 37, 303-307.	1.7	1
6	Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2018, 97, 999-1007.	1.8	50
7	Analysis of the prognostic value of BMI and the difference in its impact according to age and sex in DLBCL patients. <i>Hematological Oncology</i> , 2018, 36, 76-83.	1.7	9
8	Beta α 2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 440-446.	1.7	27
9	Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients. <i>Medical Oncology</i> , 2017, 34, 29.	2.5	9
10	The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 736-739.	1.3	13
11	PET Imaging of 18 F-FDG, 11 C-methionine, 11 C-flumazenil, and 11 C-4DST in Progressive Multifocal Leukoencephalopathy. <i>Internal Medicine</i> , 2017, 56, 1219-1223.	0.7	9
12	A convenient prognostic score consisting of the Glasgow prognostic score and serum lactate dehydrogenase predicts clinical outcome in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2460-2463.	1.3	4
13	Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model. <i>Annals of Hematology</i> , 2016, 95, 1661-1669.	1.8	23
14	Long-term complete remission in a patient with intravascular large B-cell lymphoma with central nervous system involvement. <i>OncoTargets and Therapy</i> , 2014, 7, 2133.	2.0	9
15	Mixed acinar-endocrine carcinoma of the pancreas treated with S-1. <i>Clinical Journal of Gastroenterology</i> , 2013, 6, 459-464.	0.8	21
16	A Case of Diabetic Ketoacidosis Associated with Guillain-Barre Syndrome. <i>Internal Medicine</i> , 2011, 50, 2201-2205.	0.7	8